Poseida Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Poseida Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Poseida Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $19.7M.
  • Poseida Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$62.5M, a 54.3% increase year-over-year.
  • Poseida Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$130M, a 116% decline from 2022.
  • Poseida Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$59.9M, a 57.6% increase from 2021.
  • Poseida Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$141M, a 11.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$130M -$69.6M -116% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-07
2022 -$59.9M +$81.5M +57.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2021 -$141M -$14.9M -11.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$127M -$41M -48% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 -$85.5M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.